The Abuse Potential of Remoxy®, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone
نویسندگان
چکیده
منابع مشابه
Relative Bioavailability Study of an Abuse-Deterrent Formulation of Extended-Release Oxycodone with Sequestered Naltrexone (ALO-02) Versus Immediate-Release Oxycodone Tablets in Healthy Volunteers
Abbreviations: AE: Adverse Event; ALT: Alanine Aminotransferase; AUCinf: Area Under the Plasma Concentration-Time Profile from Time 0 to Infinity; AUClast: Area Under the Curve to the Last Quantifiable Concentration; BLQ: Below Lower Limit of Quantification; BMI: Body Mass Index; BP: Blood Pressure; C24: Concentration at 24 Hours Post Dose; Clast*: the Predicted Plasma Concentration at the Last...
متن کاملManaging severe pain and abuse potential: the potential impact of a new abuse-deterrent formulation oxycodone/naltrexone extended-release product
Proper management of severe pain represents one of the most challenging clinical dilemmas. Two equally important goals must be attained: the humanitarian/medical goal to relieve suffering and the societal/legal goal to not contribute to the drug abuse problem. This is an age-old problem, and the prevailing emphasis placed on one or the other goal has resulted in pendulum swings that have result...
متن کاملSustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
BACKGROUND The development of abuse deterrent formulations is one strategy for reducing prescription opioid misuse and abuse. A putative abuse deterrent formulation of oxycodone extended release (OxyContin®) was introduced in 2010. Early reports demonstrated reduced abuse and diversion, however, an analysis of social media found 32 feasible methods to circumvent the abuse deterrent mechanism. W...
متن کاملReductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
PURPOSE Abuse of opioid analgesics for their psychoactive effects is associated with a large number of fatalities. The effect of making opioid tablets harder to crush/dissolve on opioid-related fatalities has not been assessed. The objective of this study was to assess the impact of introducing extended-release oxycodone (ERO [OxyContin(®) ]) tablets containing physicochemical barriers to crush...
متن کاملProfile of extended-release oxycodone/acetaminophen for acute pain
This article provides a historical and pharmacological overview of a new opioid analgesic that boasts an extended-release (ER) formulation designed to provide both immediate and prolonged analgesia for up to 12 hours in patients who are experiencing acute pain. This novel medication, ER oxycodone/acetaminophen, competes with current US Food and Drug Administration (FDA)-approved opioid formulat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pain Medicine
سال: 2011
ISSN: 1526-2375,1526-4637
DOI: 10.1111/j.1526-4637.2011.01093.x